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Received 10 December 2015; revised 18 January 2016; accepted 22 January 2016AbstractPostaurical injection of therapeutics was recently applied in clinical practice to treat inner ear diseases based on supposed existence of a
direct channel from the postaurical area to the inner ear. Doubting on the associated reports and aiming to provide evidence on the inner ear
uptake mechanism, the present study tracked the dynamic distribution of gadolinium-tetra-azacyclo-dodecane-tetra-acetic acid (Gd-DOTA) in
rat inner ears after postaurical injection using MRI. A targeted tympanic medial wall delivery was utilized as control. The results showed that, at
the early time points after postaurical injection, Gd-DOTA distributed mainly in tissues surrounding the bulla, temporal bone and skull and neck
space. In the inner ear, there was gradual uptake of Gd-DOTA on both the ipsilateral and contralateral sides with equal signal intensities. There
was no sign of direct channel carrying the agent from the postaurical area to the inner ear. Targeted tympanic medial wall delivery induced
significantly greater uptake of Gd-DOTA in the inner ear than did postaurical injection. At 30 min post-administration, targeted tympanic medial
wall delivery yielded 4.6-folds higher signal intensity than did postaurical injection. The total dose of Gd-DOTA delivered by the targeted
tympanic medial wall approach was only 0.1% of that delivered by postaurical injection. In conclusion, postaurical injection is a systemic
administration, which is similar to hypodermic injection, rather than a focal delivery method. By contraries, targeted tympanic medial wall
delivery induces fast and abundant uptake of Gd-DOTA in the ipsilateral inner ear without significant distribution in unwanted areas.
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(Schuknecht, 1956; Zou et al., 2014). Alternatively, Yang et al.
(2007) reported that postaurical single injection of betame-
thasone was more effective in treating intractable low-
frequency sensorineural hearing loss than oral administration
of Merislon and Sibelium for two weeks (Yang et al., 2007).
Subsequently, postaurical injection of therapeutics was also
employed to treat sudden deafness and tinnitus (Diao et al.,
2013; Li et al., 2015; Wu et al., 2015). Potential existence
of a direct transportation channel from the postaurical area to
the inner ear was reported to support the postaurical injection
approach (Lin and Yu, 2009). Postaurical injection reportedly
induced greater distribution of gadolinium chelate in the inner
ear of guinea pigs than did intravenous injection (Li et al.,gy Head and Neck Surgery. Production and hosting by Elsevier (Singapore)
eativecommons.org/licenses/by-nc-nd/4.0/).
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noninvasive method of focal drug delivery (Li et al., 2012).
I doubt on the reports associated with postaurical injection.
Based on anatomy, there is no direct transportion channel from
the postaurical area to the inner ear. Theoretically, postaurical
injection is a type of hypodermic injection that would never
induce different distribution of agents in the inner ear between
the ipsilateral and the contralateral sides. Defining postaurical
injection as a noninvasive method is conceptually incorrect
because the needle has to penetrate the skin, which is an
invasive procedure (Li et al., 2012). In order to support my
opinion, the present study tracked the dynamic distribution of
gadolinium-tetra-azacyclo-dodecane-tetra-acetic acid (Gd-
DOTA) in the surrounding tissues and inner ear of rat after
postaurical injection by following a previously reported pro-
tocol (the reported concentration should be 0.5 mol/L instead
of 0.5 mmol/L) (Li et al., 2012).
2. Materials and methods
Nine male Sprague Dawley rats, weighing between 266 g
and 635 g, were provided by and maintained in the Bio-
medicum Helsinki Laboratory Animal Centre of the Univer-
sity of Helsinki. Four rats were assigned in the experimental
group of postaurical injection of Gd-DOTA and five rats were
employed as controls receiving targeted tympanic medial wall
delivery (Zou et al., 2011). All the animal experiments were
approved by the Ethical Committee of the University of
Tampere (permit number: LSLH-2006-4143/Ym23). Animal
care and the experimental procedures were conducted in
accordance with the pertinent European legislation. During the
experiments, animals were anesthetized with isoflurane
(Piramal Healthcare, Boise, USA) using a 5% iso-
fluraneeoxygen mixture (flow-rate 1.0 L/min) for induction
and 3% isofluraneeoxygen mixture for maintenance via a
facemask with the animals' eyes protected with Viscotears®
(Novartis Healthcare A/S, Denmark).
A 4.7 T MR scanner with a bore diameter of 155 mm
(PharmaScan, Bruker BioSpin, Ettlingen, Germany) in com-
bination with a dedicated rodent head coil (linear birdcage
coil, diameter 38 mm) was used for in vivoMR measurements.
The body temperature of the rat was maintained by circulating
warm water and respiration was recorded using the Physio
Tool-1.0.b.2 program (Bruker, Ettlingen, Germany). After
postaurical injection of Gd-DOTA on the left side at a dosage
of 1.5 mmol/kg, the rat was placed in the MR scanner with
ears positioned at the isocentre for imaging. In the control
group, 2.5 ml Gd-DOTA (0.5 mol/L) (0.0031 mmol/kg in
average) was injected onto the tympanic medial wall of the left
ear using the custom-made device that was previously reported
and the rats were kept in a lateral position with the injected ear
up for 15 min before imaging (Zou et al., 2011). After
establishing inner ear geometry using a T2-weighted rapid
acquisition with relaxation enhancement (RARE) sequence,
the Gd-DOTA uptake in the inner ear was evaluated using a
T1-weighted RARE sequence and a fluid-attenuated inversion-
recovery (FLAIR) sequence for 2-dimensional (2D) and 3Dimages as reported earlier (Zou et al., 2011, 2012a). The pa-
rameters for these sequences are as follows. RARE sequence
for T2-weighted 2D images: TR/TEeff 2500/40 ms, RARE
factor 8, matrix size 256  256, slice thickness 0.8 mm, FOV
5.0  5.0 cm2, resolution 0.195  0.195 mm2, NEX 3. RARE
sequence for T1-weighted images: TR/TEeff 500/10 ms,
RARE factor 4, matrix size 256  192, slice thickness
0.5 mm, FOV 2.5  2.5 cm2, resolution 0.098  0.13 mm2,
NEX 33. RARE sequence for T1-weighted 3D images: TR/
TEeff 500/12 ms, RARE factor 16, matrix size 64  64  64,
FOV 0.89  0.89  0.89 cm3, resolution
0.139  0.139  0.139 mm3, NEX 2. FLAIR sequence for 2D
images: TR/TEeff 8000/40 ms, inversion time 1800 ms, RARE
factor 16, matrix size 256  192, slice thickness 0.5 mm, FOV
3.0  3.0 cm2, resolution 0.117  0.156 mm2, NEX 7. In the
group of postaurical injection, distribution of Gd-DOTA from
the injection site towards the surrounding area was followed
from 5 min through 42 min after injection. Distribution of Gd-
DOTA in the inner ear was followed from 45 min through
101 min after injection. MRI was repeated in one rat one week
after the injection. Animals in the control group were imaged
at the time points of 30 min, 43 min, 60 min, 70 min, 4 h, 6 h,
and 2 d after administration.
The ParaVision PV 4.0 (Bruker, Ettlingen, Germany) soft-
ware was used for post-processing and quantification of MR
images. The IBM SPSS statistics 23 software was employed
for statistical analysis. Signal intensities in the region of in-
terests (the scala tympani, scala vestibuli and vestibulum), and
the average values between the ipsilateral and contralateral
ears during the period of 45e101 min were compared using
paired-samples t-test. Signal intensities in the ipsilateral inner
ear of the targeted tympanic medial wall delivery group at the
time points of 30 min and 60 min were compared to that of the
postaurical injection group at time points of 45 min and
73 min using independent-samples t-test (this arrangement
would not underestimate the inner ear signal in the postaurical
injection group because the uptake did not reach a plateau
during the observation time of 101 min). p-values below 0.05
were considered statistically significant.
3. Results
Dynamic distribution of Gd-DOTA in the injection area and
surrounding tissues is demonstrated in Fig. 1. Owing to T2*-
related signal loss (Hagberg and Scheffler, 2013), the MRI
signal in the center of injection site (fluid), which mainly
located hypodermically, was fully eliminated during the
observation period of 42 min, but Gd-DOTA was always
detected in the skin (Fig. 1AeD). At 5 min after postaurical
injection, Gd-DOTA distributed mainly in the tissues sur-
rounding the bulla, temporal bone and skull on the ipsilateral
side (Fig. 1A). At 42 min, Gd-DOTA arrived at the nearby
neck space and the temporal bone and skull on the contralat-
eral side (Fig. 1B and C). The signal in the inner ear was weak
(Fig. 1D). In the control group of targeted tympanic medial
wall delivery, Gd-DOTAwas absent in the tissues surrounding
the bulla. However, dynamic accumulation of Gd-DOTA in the
Fig. 1. Different distribution of Gd-DOTA in the surrounding area after postaurical injection and targeted tympanic medial wall delivery in rats shown by MRI.
Gd-DOTA was injected on the left side (L), and the right side (R) without injection was assigned as control. Two-dimensional T1-weighted RARE sequence was
used to acquire the images at various time points. Bu: bulla; coch: cochlea; Gd-DOTA: Gd-DOTA liquid; Gd-DOTA-IE: Gd-DOTA in the inner ear; Gd-DOTA-LP:
Gd-DOTA in the laryngopharynx; LP: laryngophayynx; Mas: masseter; Mas-c: masseter of the contralateral side; NS: neck space; Sk: skull; Tem: temporal bone;
Tem-c: temporal bone of the contralateral side; Vest: vestibule. The scale bars on the left were created by the ParaVision PV 4.0 software.
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through 6 h after administration (Fig. 1E and F).
In the inner ear, Gd-DOTA was equally taken up on both
the ipsilateral and contralateral sides on images acquired using
either the T2-weighted RARE or FLAIR sequence (Fig. 2).
The MRI acquired using the FLAIR sequence demonstrated
higher contrast effect than that using the T1-weighted RARE
sequence. However, the latter demonstrated better anatomythan did the former. There was an insignificant difference in
the signal intensity between the ipsilateral and contralateral
sides and the uptake of Gd-DOTA in the inner ear did not
reach a plateau during the observation time of 101 min
(Fig. 3). After one week, Gd-DOTA signal disappeared in the
inner ear. In the control group of targeted tympanic medial
wall delivery, intense signal was detected in the vestibule and
lower turns of the cochlea even at the early time point of
Fig. 2. Dynamic uptake of Gd-DOTA in rat inner ear after postaurical injection detected by MRI. Gd-DOTAwas injected on the left side (L), and the right side (R)
without injection was assigned as control. Either 2-dimensional T1-weighted RARE or fluid-attenuated inversion-recovery (FLAIR) sequence was utilized to
acquire the MRI. Am: ampulla; BS: brain stem; Coch: cochlea; L: left side; R: right side; SM: scala media; ST: scala tympani; SV: scala vestibuli, Vest: vestibulum;
1H: first higher turn; 1L: first lower turn; 2H: second higher turn; 2L: second lower turn. Scale bar ¼ 5 mm.
Fig. 3. Quantificational changes in the MRI signal intensities of the rat inner ear after postaurical injection of Gd-DOTA. The images were acquired using either
T1-weighted RARE (A) or FLAIR (B) sequence. There was insignificant difference between the injection side (left, L) and control side (right, R) ears at the defined
time points (p > 0.05, paired-samples t-test). n ¼ 4. Ave: average value of the signal intensities in the scala tympani (ST), scala vestibuli (SV) and vestibulum
(Vest); AU: arbitrary unit.
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at apex of the cochlea at 60 min and evenly distributed in the
cochlea at 70 min post-administration (Fig. 4F and G).
Extremely strong signal was demonstrated in the cochlea at4 h after delivery (Fig. 4H and I). Gd-DOTA appeared in the
Eustachian tube on the ipsilateral side at 30 min and
augmented at 60 min after delivery, indicating the secretion
pathway of the excessive Gd-DOTA from the middle ear
Fig. 4. Dynamic uptake of Gd-DOTA in rat inner ear after targeted tympanic medial wall delivery shown by MRI. Images were acquired using 2-dimensional (2D)
and 3D T1-weighted RARE sequences. Am: ampulla; BS: brain stem; Coch: cochlea; ET: Eustachian tube; L: left side; R: right side; SCC: semicircular canal; ST:
scala tympani; SV: scala vestibuli; Vest: vestibulum; 1H: first higher turn; 1L: first lower turn; 2H: second higher turn; 2L: second lower turn. The scale bars on the
left were created by the ParaVision PV 4.0 software.
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tensities in the ipsilateral inner ear of the targeted tympanic
medial wall delivery group at the time points of 30 min and
60 min were significantly higher than those in the postaurical
injection group at corresponding time points (Fig. 5).
Regarding the average value in the vestibulum and scala
vestibuli and tympani, signal intensity in the targeted tympanic
medial wall delivery group at the time points of 30 min and
60 min was respectively 4.6-fold and 3.7-fold greater than
those in the postaurical injection group. Notably, the total dose
of Gd-DOTA delivered to individuals using the targeted tym-
panic medial wall approach was only 0.1% of that using
postaurical injection. Gd-DOTAwas almost undetectable from
the ipsilateral inner ear 2 d after administration. There was no
distribution of Gd-DOTA in the inner ear of the contralateral
side during the experimental period of 2 d.
4. Discussion
Distribution of Gd-DOTA in the tissues surrounding the
bulla at the earliest time after postaurical injection confirmed
that the injection was accurate. The results that postaurical
injection induced symmetric distribution of Gd-DOTA on boththe ipsilateral and contralateral sides in the inner ear suggest
that postaurical injection is not a focal delivery method but a
systemic administration similar to hypodermic injection
(1867; Mogey, 1953). It is strange that Li et al. defended that
postaurical hypodemic injection is not a systemic delivery (Li
et al., 2013). That the injected Gd-DOTA did not directly enter
the inner ear from the postaurical area proved that there is not
any direct channel from the poataurical area to the inner ear.
Instead, Gd-DOTA entered the circulation system after
diffusing in the surrounding tissues and spaces where there are
plenty of capillary beds (lymph capillaries) to enable absorp-
tion of the delivered agents (Cornford and Oldendorf, 1993;
DePace, 1981; Rose and Norris, 1990). Although there is no
ethical problem to deliver therapeutics through postaurical
injection from the scientific point of view, we should not
expect any dramatic therapeutic effect super to other systemic
administrations because the agents need to pass through the
blood-perilymph barrier and reach the target cells in contact
with the perilymph (Ulfendahl et al., 2000; Zou et al., 2003).
The blood-perilymph barrier provides limited passages for
almost all agents in order to maintain the homeostasis of the
inner ear (Brac et al., 1984; Juhn et al., 1982; Lysaght et al.,
2011; Swan et al., 2009). Injecting high dose of therapeutics
Fig. 5. Comparing the signal intensities in various inner ear area of the ipsi-
lateral side after postaurical injection and targeted tympanic medial wall de-
livery of Gd-DOTA in rats. MRIs were obtained using T1-weighted RARE
sequence. 30 min: 30 min after targeted tympanic medial wall delivery
(TMW) and 45 min after postaurical injection (PA). 60 min: 60 min after
TMW and 73 min after PA. *P < 0.05, **p < 0.01 (independent-samples
t-test). n ¼ 4 (in PA) or 5 (in TMW). Ave: average value of the signal
intensities in the scala tympani (ST), scala vestibuli (SV) and vestibulum
(Vest); AU: arbitrary unit.
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however this may cause associated adverse effects in other
organs such as the kidney and liver.
Alternatively, focal intratympanic administration bypasses
the blood-perilymph barrier and transports the agent into the
inner ear through the round and oval windows (Duan et al.,
2004; Schuknecht, 1956; Zou et al., 2014; Zou et al., 2011,
2012a, 2005, 2012b). Since agents are not diluted by the
serum that occurs in systemic administration, a high concen-
tration gradient of agents from the middle ear to the perilymph
contributes to enrichment of agents in the inner ear trans-
portated across the round and oval windows. Intratympanic
corticosteroids injections are reportedly beneficial in treating
idiopathic sudden sensorineural hearing loss, Meniere's dis-
ease and noise-induced hearing loss (Filipo et al., 2013;
Garduno-Anaya et al., 2005; Hong et al., 2009; Lavigne
et al., 2015; Rauch et al., 2011; Zhou et al., 2013). In order to
further reduce accumulation of agents in unwanted areas in
individuals, we reported a targeted tympanic medial wall de-
livery method (Zou et al., 2011). Both Gd-DOTA and super-
paramagnetic iron nanoparticles have been administered in
rats making use of this method (Zou et al., 2011, 2015a). We
also observed efficient uptake of dimeglumine gadopentetate
in the inner ear of patients with Meniere's disease after
administration using this method (Zou et al., 2015b). The
present study showed that there was insignificant distribution
of Gd-DOTA in surrounding tissues and spaces while abundant
uptake in the inner ear was achieved after targeted tympanic
medial wall delivery. The average signal intensity in the innerear of the targeted tympanic medial wall delivery group at the
time points of 30 min and 60 min was respectively 4.6-fold
and 3.7-fold greater than those in the postaurical injection
group. However, the total amount of administered agents using
the targeted tympanic medial wall approach was only 0.2% of
that using postaurical injection. It suggests that the targeted
focal delivery method is more effective than postaurical in-
jection with the possibility of maximally avoiding adverse
effects in the kidney and liver associated with drug delivery.
There are several additional scientific errors in the recently
published article (Li et al., 2013). The statement that “there is
no interaction between the in vivo contrast agent gadopentetate
dimeglumine and the inner ear tissues” contradicts to the au-
thor's own results showing appearance of the contrast agent in
the inner ear perilymph. The authors complained that intra-
venous injection did not induce endolymphatic distribution of
agents. Actually, it is unnecessary for the therapeutics to enter
the endolymph because the target cells are available to the
perilymph. More importantly, drug delivery should not disrupt
the endolymphatic space in order to maintain the inner ear
function (Hibino and Kurachi, 2006; Rask-Andersen et al.,
2006; Ulfendahl et al., 2000; Zou et al., 2013). The old term of
“blood-labyrinth barrier” in the article should be updated to
“blood-perilymph barrier and blood-endolymph barrier”
because of their significantly different composition and bio-
logical functions (Zou et al., 2010b, 2010c). The updated
terms of inner ear biological barriers are helpful for the
clinician to understand the pharmaceutical mechanism of the
inner ear therapy.
It is obvious that the physicochemical characteristics of Gd-
DOTA is not identical to that of steroids. However, the uptake
behavior of Gd-DOTA in the inner ear resembled that of ste-
roids following either intravenous or intratympanic injection
(Bird et al., 2011; Counter et al., 2000; Zou et al., 2010a, 2011,
2005, 2003, 2010b). This suggests that the results obtained
using the MRI contrast agent of Gd-DOTA can be applied to
predict the dynamics of steroids in the inner ear after similar
administrations.
To conclude, postaurical injection induced symmetric dis-
tribution of Gd-DOTA on both the ipsilateral and contralateral
sides in the inner ear in addition to the surrounding tissues and
spaces, proving that postaurical injection is a systemic admin-
istration similar to hypodermic injection rather than a focal
delivery method. By contrast, targeted tympanic medial wall
delivery induced fast and abundant uptake of Gd-DOTA in the
inner ear without significant distribution in unwanted areas.
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